Study of Angiotensin Converting Enzyme Gene Polymorphism in Egyptian Type 2 Diabetes Mellitus with Diabetic Kidney Disease

Objective: Diabetic kidney disease DKD (Diabetic nephropathy DN) is considered one of the chronic micro vascular complications of diabetes mellitus and considered the commonest cause leading to chronic renal failure and chronic renal dialysis. Genetic susceptibility has been implicated in DKD. The angiotensin converting enzyme (ACE) is one of the key roles in the renin angiotensin system cascade by converting angiotensin I to angiotensin II which plays a key role in regulation of blood pressure as well as electrolytes and fluid balance. This study addressed the association of (ACE) gene polymorphisms with DN in Egyptian (T2DM) patients. Methods: Our research comprised of 75 cases of T2DM with diabetic kidney disease, 100 cases of T2DM without DKD and 94 healthy volunteers. Different genotypes of ACE gene were determined by SSP-PCR analysis. Results: Gene polymorphism of ACE (DD, ID, II) in diabetic patient with DKD is 44%, 52%, 4% respectively and for T2DM individuals without DKD is 23%, 72%, 5% respectively. (DD) had significant higher frequencies in T2DM patients with DKD compared to those without DKD (p < 0.005) and (ID) had significant higher frequencies in T2DM without DKD (p < 0.0001). These results indicated that there is an association between ACE gene polymorphisms and susceptibility of diabetic patients to be affected by diabetic kidney disease. Conclusion: From our results, we can conclude that genotype of ACE in Egypt DD is the genotype of cases diabetic kidney disease. So the presence of D allele has a significant relation with diabetic kidney disease. Our data confirm the role of ACE in its relationship with diabetic kidney disease in Egyptian type 2 diabetic patients.

The Spectrum of Kidney Disease in Type Two Diabetic Patients: A Single-Center Study

Background: Diabetic nephropathy (DN) is the dominant reason for end-stage kidney disease linked with a rise in cardiovascular mortality rate. However, besides DN, type 2 diabetic patients may also suffer from various non-diabetic renal diseases (NDRD). Aim: The objective of the current research was to assess the occurrence and type of NDRD diagnosed by kidney biopsy in type 2 diabetic subjects, evaluate the association of various clinical and laboratory characteristics with histopathology findings, and identify essential predictors of NDRD. Methods: Retrospective analysis has been performed through medical record revision of 101 patients with type 2 diabetes undergoing percutaneous renal biopsy at Qilu Hospital of Shandong University (Jinan, China) between January 2015 and December 2020. Results: Renal biopsy results showed that NDRD was found in 59 patients (58.42%), while DN existed in 32 patients (31.68%) and 10 patients (9.90%) showed DN complicated with NDRD. Membranous nephropathy was prevailing NDRD (42%), followed by focal segmental glomerulosclerosis (11.6%) and IgA nephropathy (10.1%). In univariate analysis, patients with NDRD had older age (p Conclusions: Clinical parameters such as short duration of diabetes, older age, higher hemoglobin level, and lower proteinuria might be associated with NDRD in type 2 diabetic patients. An early diagnosis of NDRD poses a favorable renal prognosis because it requires a different approach than DN, further larger multicenter randomized prospective investigations focused on identifying possible risk markers of NDRD are still in priority.

Reference gene panel for urinary exosome-based molecular diagnostics in patients with kidney disease

BACKGROUND Kidney disease is a severe complication of diabetes that often leads to end-stage renal disease.Early diagnosis is crucial for prevention or delay.However,the current diagnostic methods,with their limitations in detecting the disease in its early stages,underscore the urgency and importance of finding new solutions.miRNAs encapsulated inside urinary exosomes(UEs)have potential as early biomarkers for kidney diseases.The need for reference miRNAs for accurate interpretation currently limits their translational potential.AIM To identify consistently expressing reference miRNAs from UEs of controls and patients with type 2 diabetesmellitus(T2DM)and biopsy-confirmed kidney diseases.METHODS miRNA profiling was performed on UEs from 31 human urine samples using a rigorous and unbiased method.The UEs were isolated from urine samples collected from healthy individuals(n=6),patients with T2DM(n=13),and T2DM patients who also had kidney diseases(including diabetic nephropathy,n=5;membranous nephropathy,n=5;and IgA nephropathy,n=2)through differential ultracentrifugation.After characterizing the UEs,miRNA expression profiling using microarray technology was conducted.RESULTS Microarray data analysis identified 14 miRNAs that were consistently expressed in UEs from 31 human samples,representing various kidney conditions:diabetic controls,diabetic nephropathy,membrane nephropathy,IgA nephropathy,and healthy controls.Through in silico analysis,we determined that 10 of these miRNAs had significant potential to serve as reference genes in UEs.CONCLUSION We identified uniformly expressing UE miRNAs that could serve as reference genes kidney disease biomarkers.

What is the optimal dialysis method for diabetic patients with end stage kidney disease?

Diabetes is one of the most catastrophic diseases ruling every corner of the world,and this has led to elevated incidents of end-stage kidney disease(ESKD).The standard treatment for ESKD is kidney transplantation/replacement,which is limited due to a deficiency of donors.Hence,dialysis has become the second-best option for treating patients with ESKD.Patients with ESKD with underlying diabetes have an additional risk of complications and infections over non-diabetic ESKD patients.Furthermore,these patients also experience variations in blood glucose levels and are more liable to develop malnutrition.This article elaborates on the different dialysis methods for ESKD patients.This editorial highlights the evidence-based studies that include randomized clinical trials,cohort studies,retrospective studies and case-control studies and suggests the most suitable type of dialysis under the following components.

泛影葡胺和碘曲仑对糖尿病大鼠肾毒性的比较

目的 :观察高渗离子造影剂 76 %泛影葡胺和等渗非离子造影剂碘曲仑对糖尿病大鼠肾毒性的不同。方法 :建立单侧肾切除糖尿病大鼠模型 ,模型建立 8周后 ,禁水 2 4h ,尾静脉分别一次性注射 76 %泛影葡胺和碘曲仑[10ml/kg ,3gI(iodine) / 10ml]。 72h后按不同要求留取血及组织标本 ,测定大鼠血肌酐和尿素氮 ,放射免疫法测定血及肾组织中ET的浓度 ,硝酸还原酶法测定NO水平 ,同时观察肾组织形态变化。结果 :糖尿病大鼠血肌酐、尿素氮与正常组相比均明显增加 (P <0 .0 1) ,HOCM组血肌酐、尿素氮较DM组进一步升高 (P <0 .0 5 ) ,且HOCM组与DM组相比 ,ET水平升高、NO含量进一步减少 (P <0 .0 5 ) ,ET/NO比值显著增高 (P <0 .0 1) ,而IOCM组各项指标均较DM组变化不明显 ;形态学观察结果亦提示 76 %泛影葡胺引起的肾脏改变较明显。结论 :高渗离子造影剂泛影葡胺可以引起糖尿病大鼠肾功能明显降低 ,而非离子等渗造影剂碘曲仑引起肾功能下降轻微 ,这可能与泛影葡胺导致了糖尿病大鼠肾组织ET/NO的严重失衡有关。